Qiagen N.V. (NYSE:QGEN) Announces Dividend of $0.25

Qiagen N.V. (NYSE:QGEN - Get Free Report) declared a dividend on Tuesday, July 1st, investing.com reports. Shareholders of record on Thursday, July 3rd will be paid a dividend of 0.25 per share on Thursday, July 10th. This represents a dividend yield of 0.52%. The ex-dividend date of this dividend is Wednesday, July 2nd.

Qiagen has a dividend payout ratio of 9.9% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Qiagen to earn $2.46 per share next year, which means the company should continue to be able to cover its $0.25 annual dividend with an expected future payout ratio of 10.2%.

Qiagen Price Performance

Shares of NYSE QGEN traded up $0.01 during midday trading on Wednesday, reaching $47.97. The company's stock had a trading volume of 519,754 shares, compared to its average volume of 1,191,252. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.83 and a current ratio of 3.37. The company has a market cap of $10.66 billion, a P/E ratio of 120.26, a P/E/G ratio of 2.45 and a beta of 0.68. The business's 50 day moving average price is $44.47 and its two-hundred day moving average price is $42.56. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $49.30.

Qiagen (NYSE:QGEN - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. The firm had revenue of $483.46 million during the quarter, compared to the consensus estimate of $465.66 million. Qiagen had a return on equity of 14.61% and a net margin of 4.68%. The company's revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.44 EPS. On average, analysts forecast that Qiagen will post 2.26 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on QGEN shares. Barclays started coverage on Qiagen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price objective for the company. Redburn Atlantic lowered shares of Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Wall Street Zen raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 15th. Robert W. Baird increased their price objective on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Finally, Bank of America boosted their target price on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a report on Thursday, June 26th. Seven research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $49.40.

Institutional Trading of Qiagen

A hedge fund recently bought a new stake in Qiagen stock. United Services Automobile Association purchased a new position in Qiagen N.V. (NYSE:QGEN - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,946 shares of the company's stock, valued at approximately $239,000. Institutional investors own 70.00% of the company's stock.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.